Likewise, the favorable impact of semaglutide on inflammatory markers such as CRP and NT-proBNP levels might provide further insight into the potential benefit of semaglutide in patients with heart failure with preserved ejection fraction (HFpEF). This evidence concerns the gene NPPB and heart failure.